Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 21
Filter
1.
Front Microbiol ; 14: 1089156, 2023.
Article in English | MEDLINE | ID: mdl-36778890

ABSTRACT

The use of immunomodulatory and metabolic modulating drugs has been considered a better strategy to improve the efficacy of conventional treatments against pathogens and metabolic diseases. L-carnitine is relevant in fatty acid metabolism and energy production by ß-oxidation, but it also has a beneficial therapeutic immunomodulatory effect. The ß-hydroxy-γ-aminophosphonate (ß-HPC) was developed, synthesized and studied in different pathologies as a more soluble and stable analog than L-carnitine, which has been studied in bacterial physiology and metabolism; therefore, we set out to investigate the direct effect of ß-HPC on the metabolism of N. brasiliensis, which causes actinomycetoma in Mexico and is underdiagnosed. To analyze the effect of ß-HPC on the metabolic capacity of the bacterium for the hydrolysis of substrate casein, L-tyrosine, egg yolk, and tween 80, Fourier transform infrared spectroscopy (FT-IR) was employed. It was found that ß-HPC increases the metabolic activity of N. brasiliensis associated with increased growth and increased hydrolysis of the substrates tested. By the effect of ß-HPC, it was observed that, in the hydrolysis of L-tyrosine, the aromatic ring and functional groups were degraded. At 1515 cm-1, any distinctive signal or peak for this amino acid was missing, almost disappearing at 839, 720, 647, and 550 cm-1. In casein, hydrolysis is enhanced in the substrate, which is evident by the presence of NH, OH, amide, and CO. In casein, hydrolysis is enhanced in the substrate, which is evident by the presence of NH, OH, amide, COO, and P = O signals, characteristic of amino acids, in addition to the increase of the amide I and II bands. In Tween 80 the H-C = and C = C signals disappear and the ether signals are concentrated, it was distinguished by the intense band at 1100 cm-1. Egg yolk showed a large accumulation of phosphate groups at 1071 cm-1, where phosvitin is located. FT-IR has served to demonstrate that ß-HPC is a hydrolysis enhancer. Furthermore, by obtaining the spectrum of N. brasiliensis, we intend to use it as a quick comparison tool with other spectra related to actinobacteria. Eventually, FT-IR may serve as a species identification option.

2.
PLoS One ; 11(9): e0162171, 2016.
Article in English | MEDLINE | ID: mdl-27683101

ABSTRACT

Amphotericin B is the most potent antimycotic known to date. However due to its large collateral toxicity, its use, although long standing, had been limited. Many attempts have been made to produce derivatives with reduced collateral damage. The molecular mechanism of polyene has also been closely studied for this purpose and understanding it would contribute to the development of safe derivatives. Our study examined polyene action, including chemical synthesis, electrophysiology, pharmacology, toxicology and molecular dynamics. The results were used to support a novel Amphotericin B derivative with increased selectivity: L-histidine methyl ester of Amphotericin B. We found that this derivative has the same form of action as Amphotericin B, i.e. pore formation in the cell membrane. Its reduced dimerization in solution, when compared to Amphotericin B, is at least partially responsible for its increased selectivity. Here we also present the results of preclinical tests, which show that the derivative is just as potent as Amphotericin B and has increased safety.

3.
J Nanobiotechnology ; 13: 83, 2015 Nov 17.
Article in English | MEDLINE | ID: mdl-26577398

ABSTRACT

BACKGROUND: The safe use in biomedicine of semiconductor nanoparticles, also known as quantum dots (QDs), requires a detailed understanding of the biocompatibility and toxicity of QDs in human beings. The biological characteristics and physicochemical properties of QDs entail new challenges regarding the management of potential adverse health effects following exposure. At certain concentrations, the synthesis of semiconductor nanoparticles of CdS using dextrin as capping agent, at certain concentration, to reduce their toxicity and improves their biocompatibility. RESULTS: This study successfully synthesized and characterized biocompatible dextrin-coated cadmium sulfide nanoparticles (CdS-Dx/QDs). The results show that CdS-Dx/QDs are cytotoxic at high concentrations (>2 µg/mL) in HepG2 and HEK293 cells. At low concentrations (<1 µg/mL), CdS-Dx/QDs were not toxic to HepG2 or HeLa cells. CdS-Dx nanoparticles only induced cell death by apoptosis in HEK293 cells at 1 µg/mL concentrations. The in vitro results showed that the cells efficiently took up the CdS-Dx/QDs and this resulted in strong fluorescence. The subcellular localization of CdS-Dx/QDs were usually small and apparently unique in the cytoplasm in HeLa cells but, in the case of HEK293 cells it were more abundant and found in cytoplasm and the nucleus. Animals treated with 100 µg/kg of CdS-Dx/QDs and sacrificed at 3, 7 and 18 h showed a differential distribution in their organs. Intense fluorescence was detected in lung and kidney, with moderate fluorescence detected in liver, spleen and brain. The biocompatibility and toxicity of CdS-Dx/QDs in animals treated daily with 100 µg/kg for 1 week showed the highest level of fluorescence in kidney, liver and brain. Less fluorescence was detected in lung and spleen. There was also evident presence of fluorescence in testis. The histopathological and biochemical analyses showed that CdS-Dx/QDs were non-toxic for rodents. CONCLUSIONS: The in vitro and in vivo studies confirmed the effective cellular uptake and even distribution pattern of CdS-Dx/QDs in tissues. CdS-Dx/QDs were biocompatible with tissues from rodents. The CdS-Dx/QDs used in this study can be potentially used in bio-imaging applications.


Subject(s)
Biocompatible Materials/chemistry , Cadmium Compounds/chemistry , Cadmium Compounds/chemical synthesis , Dextrins/chemistry , Dextrins/chemical synthesis , Diagnostic Imaging/methods , Nanoparticles/chemistry , Sulfides/chemistry , Sulfides/chemical synthesis , Cell Death , Cell Survival , Endocytosis , HEK293 Cells , HeLa Cells , Hep G2 Cells , Humans , Microscopy, Fluorescence , Nanoparticles/ultrastructure , Quantum Dots/chemistry , Tissue Distribution
4.
Int J Biomed Sci ; 10(3): 172-81, 2014 Sep.
Article in English | MEDLINE | ID: mdl-25324698

ABSTRACT

Metabolic syndrome is a prothrombotic and proinflammatory chronic state. In obesity, the adipose tissue secretes various adipokines that take part in a variety of physiological and pathophysiological processes, including immunity and inflammation. Previous studies using a liver damage model treated with the immune-modulator metallo-peptide (IMMP) showed lessening in the degree of inflammation. Therefore, this study was set up to evaluate the anti-inflammatory effect of IMMP in obese Zucker fa/fa rats. We used Zucker-Lepr fa/fa and Zucker-Lean in this protocol. The groups received IMMP 50 ng/kg by i.p., three times per week for 8 weeks. Blood samples were collected by cardiac puncture and the serum was preserved at -80°C until analysis; the liver was excised and preserved in formaldehyde 4%. Analyses were performed to determine cytokine, insulin, glucose, triglyceride and cholesterol levels in serum, and histological analysis was also performed. IMMP treatment of obese rats resulted in decreased levels of proinflammatory cytokines (leptin, lL-6, IL-1betha, INF-gamma) and a chemokine (MCP-1), and increased levels of anti-inflammatory adipokine (adiponectin). In addition, treatment decreased the damage and hepatic steatosis generated in the tissue of obese rats. The IMMP exerted an anti-inflammatory effect in obese rats and therefore may be an effective and safe therapeutic alternative in the treatment of metabolic syndrome.

5.
Pharmacology ; 94(1-2): 90-8, 2014.
Article in English | MEDLINE | ID: mdl-25227138

ABSTRACT

The purpose of this research was to describe the pharmacokinetic parameters of ß-hydroxyphosphocarnitine (ß-HPC; CAS No. 1220955-20-3) after a single oral dose in rats and rabbits as well as to assess the impact of 14 weeks of ß-HPC (100 mg/kg) treatment on the serum metabolites and liver enzymes, body weight, and hepatic steatosis of lean and obese Zucker fa/fa rats. In the case of the rat and rabbit study, the ß-HPC area under the curve, biological half-life, and clearance were 2,174.4 versus 3,128 µg ∙ h/ml, 23.7 versus 8.87 h, and 13.9 versus 151.1 ml/h in the rats versus the rabbits, respectively. The values for the time of maximal concentration were 0.58 versus 1.53 h, for the maximal concentration, they were 62.4 versus 221.4 µg/ml, and for the absorption rate constant 0.02 versus 2.40 h(-1), respectively. In the case of the Zucker fa/fa rat study, ß-HPC administered orally once a day reduced insulin, triglyceride, and cholesterol levels in the liver and serum; it also reduced weight gain and decreased liver steatosis in obese rats after 14 weeks. ß-HPC could therefore potentially be used in the treatment of metabolic syndrome.


Subject(s)
Carnitine/analogs & derivatives , Fatty Liver/prevention & control , Metabolic Syndrome/drug therapy , Obesity/drug therapy , Organophosphates/pharmacology , Administration, Oral , Animals , Area Under Curve , Carnitine/pharmacokinetics , Carnitine/pharmacology , Cholesterol/metabolism , Fatty Liver/etiology , Fatty Liver/pathology , Half-Life , Insulin/metabolism , Male , Obesity/complications , Organophosphates/pharmacokinetics , Rabbits , Rats , Rats, Wistar , Rats, Zucker , Species Specificity , Triglycerides/metabolism , Weight Gain/drug effects
6.
Basic Clin Pharmacol Toxicol ; 112(4): 222-8, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23039375

ABSTRACT

In this study, we evaluated the effect of an analogue of l-carnitine on parameters involved with Metabolic Syndrome in obese Zucker rats. Twenty-four rats were treated for 5 weeks with l-carnitine (300 mg/kg) and its analogue at two concentrations (100 and 250 mg/kg) to assess their impact on glucose, triglycerides and cholesterol in liver and blood samples, as well as the amount of liver glycogen. Liver slices were also analysed. The analogue reduced the levels of glucose, triglycerides and cholesterol in liver and the level of triglycerides in serum. At 100 mg/kg, the analogue proved more effective than l-carnitine in improving the biochemical alterations present in liver. The amount of liver glycogen content was higher in obese animals treated with both l-carnitine and the analogue. No changes on insulin and leptin were observed in animals treated. l-carnitine and its analogue reduced the microvesicular fatty infiltration in liver. This study demonstrated that the analogue tested is more potent and efficient than l-carnitine and improves the pharmacological profile of l-carnitine.


Subject(s)
Carnitine/pharmacology , Liver/drug effects , Metabolic Syndrome/drug therapy , Obesity/drug therapy , Animals , Carnitine/administration & dosage , Carnitine/analogs & derivatives , Cholesterol/metabolism , Disease Models, Animal , Dose-Response Relationship, Drug , Glucose/metabolism , Glycogen/metabolism , Insulin/metabolism , Leptin/metabolism , Liver/metabolism , Male , Rats , Rats, Zucker , Triglycerides/metabolism
7.
J Nanobiotechnology ; 10: 47, 2012 Dec 27.
Article in English | MEDLINE | ID: mdl-23270407

ABSTRACT

BACKGROUND: Semiconductor Quantum dots (QDs) have become quite popular thanks to their properties and wide use in biological and biomedical studies. However, these same properties entail new challenges in understanding, predicting, and managing potential adverse health effects following exposure. Cadmium and selenium, which are the major components of the majority of quantum dots, are known to be acutely and chronically toxic to cells and organisms. Protecting the core of nanoparticles can, to some degree, control the toxicity related to cadmium and selenium leakage. RESULTS: This study successfully synthesized and characterized maltodextrin coated cadmium sulfide semiconductor nanoparticles. The results show that CdS-MD nanoparticles are cytotoxic and embryotoxic. CdS-MD nanoparticles in low concentrations (4.92 and 6.56 nM) lightly increased the number of HepG2 cell. A reduction in MDA-MB-231 cells was observed with concentrations higher than 4.92 nM in a dose response manner, while Caco-2 cells showed an important increase starting at 1.64 nM. CdS-MD nanoparticles induced cell death by apoptosis and necrosis in MDA-MD-231 cells starting at 8.20 nM concentrations in a dose response manner. The exposure of these cells to 11.48-14.76 nM of CdS-MD nanoparticles induced ROS production. The analysis of cell proliferation in MDA-MB-231 showed different effects. Low concentrations (1.64 nM) increased cell proliferation (6%) at 7 days (p < 0.05). However, higher concentrations (>4.92 nM) increased cell proliferation in a dose response manner (15-30%) at 7 days. Exposures of chicken embryos to CdS-MD nanoparticles resulted in a dose-dependent increase in anomalies that, starting at 9.84 nM, centered on the heart, central nervous system, placodes, neural tube and somites. No toxic alterations were observed with concentrations of < 3.28 nM, neither in cells nor chicken embryos. CONCLUSIONS: Our results indicate that CdS-MD nanoparticles induce cell death and alter cell proliferation in human cell lines at concentrations higher than 4.92 nM. We also demonstrated that they are embryotoxic. However, no toxic effects were observed with doses lower than 3.28 nM in neither cells nor chicken embryos. The CdS-MD nanoparticles used in this study can be potentially used in bio-imaging applications. However, further studies using mammalian species are required in order to discard more toxic effects.


Subject(s)
Cadmium Compounds/chemistry , Cadmium Compounds/toxicity , Polysaccharides/chemistry , Polysaccharides/toxicity , Quantum Dots , Sulfides/chemistry , Sulfides/toxicity , Abnormalities, Drug-Induced/etiology , Animals , Apoptosis/drug effects , Caco-2 Cells , Cell Survival/drug effects , Chick Embryo , Embryonic Development/drug effects , Hep G2 Cells , Humans , Oxidative Stress/drug effects
8.
Ann Hepatol ; 10(4): 540-51, 2011.
Article in English | MEDLINE | ID: mdl-21911896

ABSTRACT

INTRODUCTION: Immunomodulatory drugs have been reported to have anti-inflammatory and anti-fibrotic properties. Thymic humoral factor (THF), a peptide produced in the thymus, causes a potent immunomodulatory effect on different components of the immune system. OBJECTIVE: To evaluate the effect of THF on different stages of liver damage and fibrosis induced in rats through the administration of porcine serum (PS). MATERIAL AND METHODS: PS-induced liver fibrosis models serve as a primarily immunological mechanism in the development of liver damage and fibrosis. RESULTS: The intraperitoneal administration of THF in rats with PS-induced liver damage produced a reduction of ALT and AST after 60 days. Histopathological changes in liver sections showed an improved histological appearance and lower % of fibrosis after 60 days in liver damaged rats that received THF treatment. Serum IL-6 levels were visibly reduced by THF administration after 60 days and in comparison with rats that did not receive the treatment. This was due to an increment in serum IL-10 levels caused by the administration of THF, which appears to reduce the inflammatory process by decreasing immune response. CONCLUSION: THF had beneficial effects in combating liver damage and fibrosis processes in an autoimmune model of PS-induced liver fibrosis in rats.


Subject(s)
Immunologic Factors/pharmacology , Liver Cirrhosis, Experimental/prevention & control , Liver/drug effects , Protective Agents/pharmacology , Serum , Thymus Hormones/pharmacology , Alanine Transaminase/blood , Animals , Aspartate Aminotransferases/blood , Autoimmunity/drug effects , Biomarkers/blood , Interleukin-10/blood , Interleukin-6/blood , Liver/immunology , Liver/metabolism , Liver/pathology , Liver Cirrhosis, Experimental/blood , Liver Cirrhosis, Experimental/chemically induced , Liver Cirrhosis, Experimental/immunology , Liver Cirrhosis, Experimental/pathology , Male , Rats , Rats, Wistar , Swine , Time Factors
9.
Pharmacology ; 88(1-2): 10-7, 2011.
Article in English | MEDLINE | ID: mdl-21709430

ABSTRACT

AIM: To evaluate the efficacy and safety of 2 analogs of L-carnitine on rats made insulin resistant by a high-fructose diet. METHODS: Using rats made insulin resistant by a high-fructose diet, we investigated the impact of 2 analogs of L-carnitine (25 mg/kg) and L-carnitine (250 mg/kg) on glucose, triglycerides and cholesterol blood levels, and liver glycogen. We also evaluated the safety of both analogs by the assessment of some biochemical and hematological parameters, a histological analysis and a study of embryotoxicity. RESULTS: Both analogs reduced the levels of triglycerides in the liver and plasma, but only analog 2 reduced the cholesterol levels in insulin-resistant rats. No changes were observed in glycogen content. Safety evaluations revealed alterations in blood lymphocytes and embryotoxicity data. CONCLUSION: This study demonstrated that the 2 analogs maintain the pharmacological properties of L-carnitine but have a different efficacy, potency and toxicity.


Subject(s)
Carnitine/pharmacology , Fructose/pharmacology , Insulin Resistance/physiology , Sweetening Agents/pharmacology , Vitamin B Complex/pharmacology , Animals , Blood Glucose/analysis , Body Weight , Carnitine/analogs & derivatives , Carnitine/therapeutic use , Carnitine/toxicity , Chick Embryo , Cholesterol/blood , Diet , Disease Models, Animal , Drug Evaluation, Preclinical , Embryo, Nonmammalian/drug effects , Glycogen/blood , Insulin/blood , Insulin/physiology , Liver/chemistry , Liver/metabolism , Male , Rats , Rats, Wistar , Sweetening Agents/analysis , Sweetening Agents/chemical synthesis , Sweetening Agents/toxicity , Teratogens/toxicity , Triglycerides/blood , Vitamin B Complex/therapeutic use , Vitamin B Complex/toxicity
10.
J Vet Med Sci ; 73(9): 1151-61, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21566397

ABSTRACT

Tibia fractures are common in small animal practice. Over the past decade, improvements to animal internal fracture fixation have been developed. TGF-ß1 has been shown to be crucial in the development, induction and repair of bone. In present study, we investigate the effect of local application of a graft demineralized bone matrix (DBM) along with TGF-ß1 in a model of open osteotomy induced experimentally in dogs. Tibia fracture was brought about by using an open osteotomy model in young male dogs. Fracture repair was evaluated by a histological and biochemical analysis. Collagen content, proteolytic activity and urokinase-type plasminogen activator (uPA) expression were analyzed at the end of the study. Radiographic analysis, alkaline phosphatase and hematological evaluation were performed weekly. At the fifth week, there was an improvement and restoration of bone architecture in animals treated with a graft containing TGF-ß1 (5 ng/ml) compared with the control and graft groups, as was evidenced by the presence of an early formation of wide callus and bone regeneration. In addition, local application of TGF-ß1 led to an increase in collagen and proteolytic activity. More immunopositive osteoclast and mesenchymal cells were found in bone tissue from animals treated with TGF-ß1 as compared with the control group. No changes in alkaline phosphatase, hematological and clinical parameters were observed. This study shows that the combined use of DBM along with TGF-ß1 is able to improve and accelerate the bone repair.


Subject(s)
Bone Matrix , Bone Transplantation/veterinary , Dog Diseases/surgery , Fractures, Bone/veterinary , Transforming Growth Factor beta1/pharmacology , Animals , Bone Transplantation/methods , Dogs , Fracture Healing/physiology , Fractures, Bone/surgery , Male
11.
J Food Sci ; 76(4): R112-24, 2011 May.
Article in English | MEDLINE | ID: mdl-22417366

ABSTRACT

It has been well established that complex mixtures of phytochemicals in fruits and vegetables can be beneficial for human health. Moreover, it is becoming increasingly apparent that phytochemicals can influence the pharmacological activity of drugs by modifying their absorption characteristics through interactions with drug transporters as well as drug-metabolizing enzyme systems. Such effects are more likely to occur in the intestine and liver, where high concentrations of phytochemicals may occur. Alterations in cytochrome P450 and other enzyme activities may influence the fate of drugs subject to extensive first-pass metabolism. Although numerous studies of nutrient-drug interactions have been published and systematic reviews and meta-analyses of these studies are available, no generalizations on the effect of nutrient-drug interactions on drug bioavailability are currently available. Several publications have highlighted the unintended consequences of the combined use of nutrients and drugs. Many phytochemicals have been shown to have pharmacokinetic interactions with drugs. The present review is limited to commonly consumed fruits and vegetables with significant beneficial effects as nutrients and components in folk medicine. Here, we discuss the phytochemistry and pharmacokinetic interactions of the following fruit and vegetables: grapefruit, orange, tangerine, grapes, cranberry, pomegranate, mango, guava, black raspberry, black mulberry, apple, broccoli, cauliflower, watercress, spinach, tomato, carrot, and avocado. We conclude that our knowledge of the potential risk of nutrient-drug interactions is still limited. Therefore, efforts to elucidate potential risks resulting from food-drug interactions should be intensified in order to prevent undesired and harmful clinical consequences.


Subject(s)
Biological Transport , Food-Drug Interactions , Fruit/metabolism , Inactivation, Metabolic , Plant Extracts/pharmacokinetics , Vegetables/metabolism , Biological Availability , Citrus/metabolism , Citrus paradisi/metabolism , Citrus sinensis/metabolism , Humans , Lythraceae/metabolism , Malus/metabolism , Medicine, Traditional , Morus/metabolism , Nutritive Value , Risk Factors , Vitis/metabolism
12.
J Food Sci ; 75(1): T6-12, 2010.
Article in English | MEDLINE | ID: mdl-20492211

ABSTRACT

Coriander has been used as a spice and medicinal plant for centuries. Several studies have described its biological properties and some reports have indicated its pharmacological actions in some human pathology. However, data on its toxicity and metabolism are limited or null, and no research has been conducted with mammalian cells. The purpose of this study was to evaluate the mutagenicity and safety of Coriandrum sativum extract. The mutagenic effects of C. sativum extract were evaluated by Ames test. Mutagenicity was present when the C. sativum extract was used in high concentrations in both tested strains (Salmonella typhimurium TA97 and TA102). Our research showed that C. sativum extract reduced the cell survival of human cell lines (WRL-68 and 293Q cells) by inducing apoptosis and necrosis in the cases where extract concentration was the highest. The C. sativum extract altered the cell cycle; it increased the G1 phase of hepatic cells and reduced the G2+M phase in both cell lines in a dose-response manner. These results showed correlation with a reduction in the mitotic index. The extract also induced severe malformations during embryonic development. Exposure of chicken embryos to the C. sativum extract resulted in a dose-dependent increase of anomalies. Present results show that C. sativum extract reduced the axial skeleton and affected the neural tube, the somites, the cardiovascular structures, and the eye. According to the present results, the C. sativum aqueous extract cannot be considered safe. These results indicate that some significant adverse effects of C. sativum extract could be observed in vivo.


Subject(s)
Coriandrum/chemistry , Mutagens/pharmacology , Plant Extracts/isolation & purification , Plant Leaves/chemistry , Animals , Apoptosis/drug effects , Cell Cycle/drug effects , Cell Line , Cell Survival/drug effects , Embryonic Development/drug effects , Epithelial Cells/drug effects , Epithelial Cells/physiology , Female , Fertility/drug effects , G1 Phase/drug effects , Humans , Kidney/drug effects , Kidney/embryology , Liver/drug effects , Liver/embryology , Liver/pathology , Liver/physiology , Necrosis , Oils, Volatile/analysis , Plant Extracts/pharmacology , Rats , Safety
13.
Toxicol Appl Pharmacol ; 227(1): 125-35, 2008 Feb 15.
Article in English | MEDLINE | ID: mdl-18037151

ABSTRACT

In Mexico, local empirical knowledge about medicinal properties of plants is the basis for their use as home remedies. It is generally accepted by many people in Mexico and elsewhere in the world that beneficial medicinal effects can be obtained by ingesting plant products. In this review, we focus on the potential pharmacologic bases for herbal plant efficacy, but we also raise concerns about the safety of these agents, which have not been fully assessed. Although numerous randomized clinical trials of herbal medicines have been published and systematic reviews and meta-analyses of these studies are available, generalizations about the efficacy and safety of herbal medicines are clearly not possible. Recent publications have also highlighted the unintended consequences of herbal product use, including morbidity and mortality. It has been found that many phytochemicals have pharmacokinetic or pharmacodynamic interactions with drugs. The present review is limited to some herbal medicines that are native or cultivated in Mexico and that have significant use. We discuss the cultural uses, phytochemistry, pharmacological, and toxicological properties of the following plant species: nopal (Opuntia ficus), peppermint (Mentha piperita), chaparral (Larrea divaricata), dandlion (Taraxacum officinale), mullein (Verbascum densiflorum), chamomile (Matricaria recutita), nettle or stinging nettle (Urtica dioica), passionflower (Passiflora incarnata), linden flower (Tilia europea), and aloe (Aloe vera). We conclude that our knowledge of the therapeutic benefits and risks of some herbal medicines used in Mexico is still limited and efforts to elucidate them should be intensified.


Subject(s)
Herbal Medicine , Humans , Mexico , Risk Assessment
14.
Pharmacology ; 81(1): 41-9, 2008.
Article in English | MEDLINE | ID: mdl-17823541

ABSTRACT

AIM: To evaluate the effect of genistein on the fibrosis and matrix degradation caused by experimentally induced fibrosis in rats. METHODS: Hepatic fibrosis was brought about by chronic administration of carbon tetrachloride to rats. To evaluate the effect of genistein on liver fibrosis and function, total collagen content and proteolytic activity in the liver were quantified. Urokinase-type plasminogen activator (uPA) expression during experimental fibrosis was localized by immunohistochemistry. Histopathological changes were evaluated using light and electron microscopy. RESULTS: Animals with fibrosis and treated with genistein showed an important reduction (73%) in hepatic collagen content as well as an improvement in liver function (p < 0.001). Genistein increased the capacity of the liver to degrade type I collagen and Matrigel (3.1- and 3.7-fold, respectively; p < 0.001) in animals with liver fibrosis. Genistein increased the number of uPA-immunoreactive cells. The increase in the uPA expression correlated with an increase in proteolytic activity. Histological analysis revealed a reduction in the number of fiber septa in pericentral and perisinusoidal areas. Transmission electron micrographs of livers from animals with fibrosis and treated with genistein showed a reduction in the number of hepatic stellate cells activated and a smaller number of collagen fibers. CONCLUSION: Genistein is able to improve the liver after injury and fibrosis induced by chronic administration of carbon tetrachloride. This finding suggests that genistein has antifibrogenic potential and could therefore be useful for treating chronic liver disease.


Subject(s)
Genistein/therapeutic use , Liver Cirrhosis/prevention & control , Liver , Peptide Hydrolases/metabolism , Protein Kinase Inhibitors/therapeutic use , Urokinase-Type Plasminogen Activator/biosynthesis , Animals , Carbon Tetrachloride , Collagen Type I/metabolism , Disease Models, Animal , Genistein/administration & dosage , Genistein/pharmacology , Immunohistochemistry , Liver/drug effects , Liver/enzymology , Liver/metabolism , Liver/ultrastructure , Liver Cirrhosis/enzymology , Liver Cirrhosis/metabolism , Liver Cirrhosis/pathology , Liver Function Tests , Male , Microscopy, Electron, Transmission , Protein Kinase Inhibitors/administration & dosage , Protein Kinase Inhibitors/pharmacology , Rats , Rats, Wistar
15.
J Pharm Pharmacol ; 59(5): 719-25, 2007 May.
Article in English | MEDLINE | ID: mdl-17524238

ABSTRACT

Among the eight Calophyllum species found on the American continent, Calophyllum brasiliense is the most widely distributed. Chemical analysis of this species has shown the presence of xanthones with cancer chemopreventive properties and antifungal activity. Recently, three new coumarins with antineoplastic properties have been found. In this study, we have evaluated the biological effects of the antiproliferative activity of coumarins isolated from C. brasiliense on the survival, cell cycle and apoptosis of cells in-vitro and their antitumour effects in mice. The cytological study showed that coumarins from C. brasiliense reduce the survival of BMK cells (baby mouse kidney cells) by inducing apoptosis and, to a lesser degree, necrosis. The cell cycle was arrested in S-phase and the division of BMK cells was inhibited. Coumarins had caused a reduction of experimental tumours in 83% of animals by the end of the treatment. Therefore, coumarins have the potential to be used alone or in combination with other antineoplastic drugs, and they might increase the effectiveness of other treatments for cancer.


Subject(s)
Antineoplastic Agents/pharmacology , Calophyllum/chemistry , Coumarins/pharmacology , Plant Extracts/pharmacology , Animals , Antineoplastic Agents/isolation & purification , Apoptosis/drug effects , Cell Cycle/drug effects , Cell Proliferation/drug effects , Cell Survival/drug effects , Coumarins/isolation & purification , Disease Models, Animal , Dose-Response Relationship, Drug , Drug Screening Assays, Antitumor , Female , Mice , Mice, Inbred BALB C , Mitosis/drug effects , Necrosis , Neoplasms/drug therapy , Plant Extracts/isolation & purification , Plants, Medicinal/chemistry , Vincristine/pharmacology
16.
Ann Hepatol ; 6(1): 41-7, 2007.
Article in English | MEDLINE | ID: mdl-17297428

ABSTRACT

Fibrosis accompanies most chronic liver disorders and is a major factor contributing to hepatic failure. Therefore, the need for an effective treatment with the aim of modifying the clinical course of this disease is evident. The aim of this work is to determine whether genistein, which has been shown to modulate the physiology and pathophysiology of liver, is able to decrease experimental liver fibrosis and cholestasis. In male Wistar rats, the common bile duct was ligated. Administration of genistein (5 microg rat-1, day-1, p.o.) began four weeks after biliary obstruction and continued for a further four weeks. The liver was used for histological and ultrastructural analysis and for collagen quantification (hydroxyproline content). The degradation of Matrigel(R) and collagen type I was determined in homogenized liver. Bilirubins and enzyme activities were measured in serum. Genistein was able to improve normal liver histology, ultrastructure, collagen content, and biochemical markers of liver damage. It also increased Matrigel(R) and collagen type I degradation. In summary, the present report shows that genistein inhibits the fibrosis and cholestasis induced by prolonged biliary obstruction in the rat. Genistein has therapeutic potential against liver fibrosis.


Subject(s)
Cholestasis, Extrahepatic/complications , Enzyme Inhibitors/therapeutic use , Genistein/therapeutic use , Liver Cirrhosis, Experimental/drug therapy , Animals , Cholestasis, Extrahepatic/drug therapy , Cholestasis, Extrahepatic/pathology , Chronic Disease , Follow-Up Studies , Liver/ultrastructure , Liver Cirrhosis, Experimental/etiology , Liver Cirrhosis, Experimental/pathology , Male , Microscopy, Electron , Rats , Rats, Wistar , Time Factors , Treatment Outcome
17.
Biochem Pharmacol ; 73(6): 814-23, 2007 Mar 15.
Article in English | MEDLINE | ID: mdl-17196553

ABSTRACT

Androgen-independent prostate cancer cells DU-145 express a number of G protein-coupled receptors, including histamine H1 receptors. There is evidence for the presence of beta-adrenoceptors in the human prostate, and in this work we set out to characterise the expression of beta-adrenoceptors by DU-145 cells, their linking to cyclic AMP (cAMP) formation and the possible modulation by histamine H1 receptors of beta-adrenoceptor function. Saturation [3H]-dihydroalprenolol binding indicated that DU-145 cells express moderate levels of beta-adrenoceptors (22.7+/-2.5 fmol/mg protein), which belong to the beta2-subtype as assessed by inhibition by the antagonists ICI-118,551 and CGP-20712A. Inhibition of [3H]-dihydroalprenolol binding by agonists (noradrenaline, adrenaline and isoproterenol) showed the presence of both high-(53-59%) and low-affinity binding sites. beta-Adrenoceptor stimulation with isoproterenol resulted in robust [3H]-cAMP accumulation (10-30-fold of basal, EC50 142 nM; pEC50 6.85+/-0.05). While not having effect of its own on basal [3H]-cAMP accumulation, histamine significantly augmented the beta2-adrenoceptor-induced response (overall effect 152+/-6% of isoproterenol alone) with EC50 1.35 microM (pEC50 5.87+/-0.06). This effect was independent of extracellular Ca2+, insensitive to antagonists/agonists at H1, H2 or H3/H4 receptors and mimicked by drugs containing an imidazole ring in their chemical structure and by imidazole itself. Taken together, our results show that in DU-145 cells histamine augments beta2-adrenoceptor-induced cAMP independently of the activation of known histamine receptors. The effect may involve other mechanisms such as allosteric modulation of beta2-adrenoceptors by the imidazole moiety of histamine.


Subject(s)
Cyclic AMP/metabolism , Histamine/pharmacology , Prostatic Neoplasms/metabolism , Receptors, Adrenergic, beta-2/physiology , Receptors, Histamine/physiology , Cell Line, Tumor , Dihydroalprenolol/metabolism , Humans , Isoproterenol/pharmacology , Male , Zinc/pharmacology
18.
Bioorg Med Chem ; 13(23): 6521-8, 2005 Dec 01.
Article in English | MEDLINE | ID: mdl-16122928

ABSTRACT

The synthesis of some monocyclic analogues of mycophenolic acid in which the lactone ring has been eliminated, leaving the aromatic ring intact and the same oxygenated substituents flanking the hexenoic acid side chain with an (E)-geometry at the double bond, has been accomplished via the Johnson ortho ester Claisen rearrangement. The synthetic methodology reported here allows the preparation of mycophenolic acid analogues bearing alkyl substituents at the alpha- and beta-positions on the side chain.


Subject(s)
Esters/chemistry , Mycophenolic Acid/analogs & derivatives , Mycophenolic Acid/chemical synthesis , Cell Line , Cell Survival/drug effects , Cyclization , Humans , Molecular Structure , Mycophenolic Acid/chemistry , Mycophenolic Acid/toxicity
19.
Arch Med Res ; 36(4): 311-6, 2005.
Article in English | MEDLINE | ID: mdl-15950068

ABSTRACT

BACKGROUND: Human papillomavirus (HPV) infection is the most prevalent factor in anogenital cancers. However, epidemiological surveys and molecular data indicate that viral presence is not enough to induce cervical cancer, suggesting that cellular factors could play a key role. One of the most important genes involved in cancer development is the RAS oncogene, and activating mutations in this gene have been associated with HPV infection and cervical neoplasia. Thus, we determined the effect of HRAS oncogene expression on cell proliferation in a cell line immortalized by E6 and E7 oncogenes. METHODS: HPV positive human cervical carcinoma-derived cell lines (HeLa), previously transfected with the HRAS oncogene or the empty vector, were used. We first determined the proliferation rate and cell cycle profile of these cells by using flow cytometry and BrdU incorporation assays. In order to determine the signaling pathway regulated by HRAS and implicated in the alteration of proliferation of these cells, we used specific chemical inhibitors to inactivate the Raf and PI3K pathways. RESULTS: We observed that HeLa cells stably transfected with oncogenic HRAS progressed faster than control cells on the cell cycle by reducing their G1 phase. Additionally, HRAS overexpression accelerated the G1/S transition. Specific chemical inhibitors for PI3K and MEK activities indicated that both PI3K/AKT and RAF/MEK/ERK pathways are involved in the HRAS oncogene-induced reduction of the G1 phase. CONCLUSIONS: Our results suggest that the HRAS oncogene could play an important role in the development of cervical cancer, in addition to the presence of HPV, by reducing the G1 phase and accelerating the G1/S transition of infected cells.


Subject(s)
Genes, ras , Uterine Cervical Neoplasms/genetics , Uterine Cervical Neoplasms/pathology , Blotting, Western , Bromodeoxyuridine/pharmacology , Cell Cycle , Cell Line, Tumor , Cell Proliferation , DNA-Binding Proteins/genetics , Enzyme Inhibitors/pharmacology , Female , Flow Cytometry , G1 Phase , HeLa Cells , Humans , Mutation , Oncogene Proteins, Viral/genetics , Papillomaviridae/genetics , Phosphatidylinositol 3-Kinases/metabolism , Phosphorylation , S Phase , Time Factors , Transfection , Uterine Cervical Neoplasms/virology
20.
Pharmacology ; 73(1): 23-30, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15452360

ABSTRACT

The aim of this study was to determine whether transforming growth factor-beta1 (TGF-beta1) induces the synthesis, release and gene expression of urokinase-type plasminogen activator (uPA) in hepatic stellate cells. In addition to stimulating collagen production, TGF-beta1 induced the morphological and phenotypical changes characteristic of hepatic stellate cell activation. However, these changes accentuated in cells previously activated with acetaldehyde. TGF-beta1 increased to 2-fold uPA activity in lysates from quiescent cells, and to 3.5-fold in activated cells, and induced uPA gene expression to the same extent in both activated and non-activated cells. TGF-beta1 had a modest stimulatory action on the release of uPA into the conditioned medium, but reduced acetaldehyde-induced release, as demonstrated by Western blot analysis. In accord, whereas TGF-beta1 produces no effect on uPA activity in the conditioned media from quiescent cells, it significantly reduces the stimulatory action of acetaldehyde. These results show that the activity and gene expression of uPA are regulated by both acetaldehyde and TGF-beta1 and that the proteolytic activity in the extracellular space is reduced by the influence of TGF-beta1. Further studies on the molecular mechanisms responsible for the regulation of the plasminogen system by TGF-beta1 and other molecules in the presence of acetaldehyde will contribute to a better understanding of the processes involved in fibrogenesis.


Subject(s)
Acetaldehyde/pharmacology , Hepatocytes/metabolism , Liver/drug effects , Transforming Growth Factor beta/pharmacology , Urokinase-Type Plasminogen Activator/biosynthesis , Animals , Blotting, Western , Carbon Tetrachloride Poisoning/pathology , Collagen/metabolism , Culture Media, Conditioned , Hepatocytes/drug effects , Liver/cytology , RNA/biosynthesis , RNA/genetics , Rats , Reverse Transcriptase Polymerase Chain Reaction , Transforming Growth Factor beta1 , Urokinase-Type Plasminogen Activator/genetics , Urokinase-Type Plasminogen Activator/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...